MRI software developer NeuroGrafix of Santa Monica, CA, is claiming that Canadian intraoperative MRI technology developer IMRIS of Winnipeg, Manitoba, has developed technology that infringes on its patents for diffusion tensor imaging (DTI) technology.
NeuroGrafix said that its founder and CEO, Dr. Aaron Filler, developed the first diffusion anisotropy-based tractograms, which the firm claims is the technology that underlies modern DTI. He received patents for his DTI work, as well as patents for portable maneuverable MRI scanners.
Tractography based on DTI is used to avoid damage to critical white matter tracts during tumor surgery and resection of vascular malformations, and in guidance of stereotactic radiosurgery, NeuroGrafix said. Intraoperative MRI systems provide the opportunity to depict and update the white matter tract information as the surgery or treatment progresses, thus improving patient safety.
NeuroGrafix has begun notifying IMRIS customers that they cannot use IMRIS systems for DTI without obtaining a license under U.S. Patent 5,560,360. The company has already won a $900,000 settlement from Oak Tree Medical Center in Pasadena, CA, covering MR neurography.
Related Reading
MRIS gets FDA nod, September 8, 2009
IMRIS wins CE Mark for MR angiography suite, May 1, 2009
IMRIS lands China install, April 16, 2009
IMRIS launches research initiative, February 20, 2009
NeuroGrafix settles patent dispute, June 26, 2009
Copyright © 2009 AuntMinnie.com
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
